Switch to Lisdexamfetamine in the Treatment of Attention-Deficit Disorder at a Psychiatric Outpatient Clinic for School-Aged Children: A Danish Cohort Study
Journal of Child and Adolescent Psychopharmacology,Volume 34, Issue 3, Page 137-147, April 2024. (Source: Journal of Child and Adolescent Psychopharmacology)
Source: Journal of Child and Adolescent Psychopharmacology - April 11, 2024 Category: Pediatrics Authors: Nanna Roed S øndergaard Karen Busk N ørøxe Anders Helles Carlsen Stine Helene Randing Pernille Warrer Per Hove Thomsen Loa Clausen Source Type: research
Memory loss induced by lisdexamfetamine in the rat: A behavioral, electrophysiological, and histopathological Study
Behav Brain Res. 2024 Mar 16:114963. doi: 10.1016/j.bbr.2024.114963. Online ahead of print.ABSTRACTLisdexamfetamine (LDX) is one of the drugs commonly used to treat attention deficit hyperactivity disorder (ADHD). However, its neurological side effects, particularly on cognition, are not fully understood. The present study focused on memory in rats treated with four weeks of LDX injection. We compared LDX-treated rats with control ones, using several methods to evaluate the behavioral responses and electrophysiological, molecular, and histological properties in the hippocampus. Our findings demonstrated that subchronic adm...
Source: Behavioural Brain Research - March 18, 2024 Category: Neurology Authors: Seyedeh Naghmeh Nourirad Amhr-Hossein Bayat Moitaba Sani Amirreza Beirami Maral Hasanzadeh Susan Roustaee Mobina Fathi Kimia Vakili Siavash Parvardeh Gholam Hossein Meftahi Nahid Sarahian Fariba Khodagholi Abbas Aliaghaei Hojjat-Allah Abbaszadeh Meysam Ha Source Type: research
Memory loss induced by lisdexamfetamine in the rat: A behavioral, electrophysiological, and histopathological Study
Behav Brain Res. 2024 Mar 16:114963. doi: 10.1016/j.bbr.2024.114963. Online ahead of print.ABSTRACTLisdexamfetamine (LDX) is one of the drugs commonly used to treat attention deficit hyperactivity disorder (ADHD). However, its neurological side effects, particularly on cognition, are not fully understood. The present study focused on memory in rats treated with four weeks of LDX injection. We compared LDX-treated rats with control ones, using several methods to evaluate the behavioral responses and electrophysiological, molecular, and histological properties in the hippocampus. Our findings demonstrated that subchronic adm...
Source: Behavioural Brain Research - March 18, 2024 Category: Neurology Authors: Seyedeh Naghmeh Nourirad Amhr-Hossein Bayat Moitaba Sani Amirreza Beirami Maral Hasanzadeh Susan Roustaee Mobina Fathi Kimia Vakili Siavash Parvardeh Gholam Hossein Meftahi Nahid Sarahian Fariba Khodagholi Abbas Aliaghaei Hojjat-Allah Abbaszadeh Meysam Ha Source Type: research
Memory loss induced by lisdexamfetamine in the rat: A behavioral, electrophysiological, and histopathological Study
Behav Brain Res. 2024 Mar 16:114963. doi: 10.1016/j.bbr.2024.114963. Online ahead of print.ABSTRACTLisdexamfetamine (LDX) is one of the drugs commonly used to treat attention deficit hyperactivity disorder (ADHD). However, its neurological side effects, particularly on cognition, are not fully understood. The present study focused on memory in rats treated with four weeks of LDX injection. We compared LDX-treated rats with control ones, using several methods to evaluate the behavioral responses and electrophysiological, molecular, and histological properties in the hippocampus. Our findings demonstrated that subchronic adm...
Source: Behavioural Brain Research - March 18, 2024 Category: Neurology Authors: Seyedeh Naghmeh Nourirad Amhr-Hossein Bayat Moitaba Sani Amirreza Beirami Maral Hasanzadeh Susan Roustaee Mobina Fathi Kimia Vakili Siavash Parvardeh Gholam Hossein Meftahi Nahid Sarahian Fariba Khodagholi Abbas Aliaghaei Hojjat-Allah Abbaszadeh Meysam Ha Source Type: research
Memory loss induced by lisdexamfetamine in the rat: A behavioral, electrophysiological, and histopathological Study
Behav Brain Res. 2024 Mar 16:114963. doi: 10.1016/j.bbr.2024.114963. Online ahead of print.ABSTRACTLisdexamfetamine (LDX) is one of the drugs commonly used to treat attention deficit hyperactivity disorder (ADHD). However, its neurological side effects, particularly on cognition, are not fully understood. The present study focused on memory in rats treated with four weeks of LDX injection. We compared LDX-treated rats with control ones, using several methods to evaluate the behavioral responses and electrophysiological, molecular, and histological properties in the hippocampus. Our findings demonstrated that subchronic adm...
Source: Behavioural Brain Research - March 18, 2024 Category: Neurology Authors: Seyedeh Naghmeh Nourirad Amhr-Hossein Bayat Moitaba Sani Amirreza Beirami Maral Hasanzadeh Susan Roustaee Mobina Fathi Kimia Vakili Siavash Parvardeh Gholam Hossein Meftahi Nahid Sarahian Fariba Khodagholi Abbas Aliaghaei Hojjat-Allah Abbaszadeh Meysam Ha Source Type: research
Memory loss induced by lisdexamfetamine in the rat: A behavioral, electrophysiological, and histopathological Study
Behav Brain Res. 2024 Mar 16:114963. doi: 10.1016/j.bbr.2024.114963. Online ahead of print.ABSTRACTLisdexamfetamine (LDX) is one of the drugs commonly used to treat attention deficit hyperactivity disorder (ADHD). However, its neurological side effects, particularly on cognition, are not fully understood. The present study focused on memory in rats treated with four weeks of LDX injection. We compared LDX-treated rats with control ones, using several methods to evaluate the behavioral responses and electrophysiological, molecular, and histological properties in the hippocampus. Our findings demonstrated that subchronic adm...
Source: Brain Research - March 18, 2024 Category: Neurology Authors: Seyedeh Naghmeh Nourirad Amhr-Hossein Bayat Moitaba Sani Amirreza Beirami Maral Hasanzadeh Susan Roustaee Mobina Fathi Kimia Vakili Siavash Parvardeh Gholam Hossein Meftahi Nahid Sarahian Fariba Khodagholi Abbas Aliaghaei Hojjat-Allah Abbaszadeh Meysam Ha Source Type: research
Medication Treatment for ADHD Linked to Lower Two-Year Risk of Dying
People with attention-deficit/hyperactivity disorder (ADHD) who begin taking medications for the condition within three months of their diagnosis may have a lower risk of dying within two years compared with their peers who do not take ADHD medications, astudy inJAMA has found.Zheng Chang, Ph.D., of the Karolinska Institutet in Stockholm and colleagues examined data from 148,578 Swedish individuals aged 6 to 64 years who had an incident diagnosis of ADHD from 2007 through 2018 and no ADHD medication dispensation for at least 18 months prior to their diagnosis. They followed the patients from ADHD diagnosis for two years or...
Source: Psychiatr News - March 15, 2024 Category: Psychiatry Tags: ADHD attention-deficit/hyperactivity disorder JAMA Karolinska Institutet medication mortality stimulants unnatural deaths Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
Stimulant prodrugs: A pharmacological and clinical assessment of their role in treating ADHD and binge-eating disorder
Adv Pharmacol. 2024;99:251-286. doi: 10.1016/bs.apha.2023.10.002. Epub 2023 Oct 25.ABSTRACTIn this review, we critically evaluate the contribution of prodrugs to treating two related psychiatric disorders, attention-deficit hyperactivity disorder (ADHD) and binge-eating disorder (BED). ADHD is characterized by inattentiveness, distractibility, impulsiveness, and hyperactivity. BED is also an impulse-control disorder which leads to frequent, compulsive episodes of excessive eating (binges). Lisdexamfetamine (LDX; prodrug of d-amphetamine) is approved to treat both ADHD and BED. Serdexmethylphenidate (SDX; prodrug of d-threo...
Source: Advances in Pharmacology - March 11, 2024 Category: Drugs & Pharmacology Authors: David J Heal Jane Gosden Sharon L Smith Source Type: research
